TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05631769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet agent duration
Description: Patients who receive percutaneous coronary intervention for coronary artery disease will be randomized to arms with different DAPT strategies.~The randomization will be stratified according to the High bleeding risk (defined according to the ARC-HBR criteria).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antiplatelet agent duration
Description: Patients who receive percutaneous coronary intervention for coronary artery disease will be randomized to arms with different DAPT strategies.~The randomization will be stratified according to the High bleeding risk (defined according to the ARC-HBR criteria).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antiplatelet agent duration
Description: Patients who receive percutaneous coronary intervention for coronary artery disease will be randomized to arms with different DAPT strategies.~The randomization will be stratified according to the High bleeding risk (defined according to the ARC-HBR criteria).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet agent duration
Description: Patients who receive percutaneous coronary intervention for coronary artery disease will be randomized to arms with different DAPT strategies.~The randomization will be stratified according to the High bleeding risk (defined according to the ARC-HBR criteria).
Study: NCT03835312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sequential transplantation
Description: After successful matching of umbilical cord blood stem cells, patients will receive pretreatment and chemotherapy under protective isolation, followed by thawing and reinfusion of umbilical cord blood stem cells. Immunosuppressive agents will be used for GVHD prevention and anti-infection support will be provided after reinfusion. The status of umbilical cord blood stem cell implantation, immune reconstruction and therapeutic effect will be evaluated. Islet transplantation will be performed in those who meet the conditions. The long-term prognosis will be observed by long-term follow-up.
Study: NCT04757896

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral costoclavicular approach
Description: USG guided lateral costoclavicular approach for brachial plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial costoclavicular approach
Description: USG guided medial costoclavicular approach for brachial plexus block
Study: NCT02618148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESTROGEN HERBALS 21
Description: Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5 mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESTROGEN HERBALS 28
Description: Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days.
Study: NCT00646282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxercalciferol
Description: The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH\>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH \<300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
Study: NCT01537809

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Subjects are told to take vitamin D daily for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Subjects are told to take vitamin D daily for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Subjects are told to take vitamin D daily for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Subjects are asked to take vitamin D orally, daily for six months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Subjects are asked to take vitamin D orally, daily for six months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Subjects are asked to take vitamin D orally, daily for six months.
Study: NCT02903095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1439

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03312764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online diabetes prevention program
Description: Digital delivery of Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: One-on-one or small group sessions with a dietitian or a trained health professional to advise on physical activity, healthful nutrition and risk reduction for diabetes.
Study: NCT03187899

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine
Description: 0.5% of Ropivacaine will be used patients in both groups. Ropivacaine is very common in the investigator's practice of regional anesthesia. The investigator has experienced minimal adverse effects with 0.5% Ropivacaine used in volume suggested in our study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.5% of Ropivacaine will be used patients in both groups. Ropivacaine is very common in the investigator's practice of regional anesthesia. The investigator has experienced minimal adverse effects with 0.5% Ropivacaine used in volume suggested in our study.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: 5-10cc of Normal Saline will be given to patients receiving a traditional interscalene block and a sham superficial plexus block.
Study: NCT01143610

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Newly forming bone technique for root coverage
Description: A granulation tissue will be obtained 21-25 days after the creation of an alveolar socket and grafted to receptor site.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subepithelial connective tissue graft for root coverage.
Description: A subepithelial connective tissue graft will be used for the treatment of Miller class I or II deep recessions.
Study: NCT00203892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified CEA peptide (10mcg)
Description: Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified CEA peptide (100mcg)
Description: Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified CEA peptide (1000mcg)
Description: Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
Study: NCT04037683

Intervention type: DRUG
Intervention: Misoprostol Oral Tablet
Description: Misoprostol 25mcg orally given 2-hourly

Intervention type: DRUG
Intervention: Misoprostol Oral Tablet
Description: Misoprostol 25mcg orally given 2-hourly

Intervention type: DRUG
Intervention: Oxytocin
Description: Oxytocin infusion
Study: NCT01876628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flucloxacillin
Description: Intravenous or oral Flucloxacillin. Minimum dose 500mg four times each day. Target duration 5 days less pre-recruitment beta-lactam duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flucloxacillin
Description: Intravenous or oral Flucloxacillin. Minimum dose 500mg four times each day. Target duration 5 days less pre-recruitment beta-lactam duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days
Study: NCT01181895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol Inhalation Powder
Description: Salmeterol inhalation powder inhaled orally twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhalation Powder NDPI
Description: Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
Study: NCT03025698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Tablet for oral use, once daily or Powder for oral suspension (PfOS), once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Tablet for oral use, once daily or Powder for oral suspension (PfOS), once daily
Study: NCT01181895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inhalation Powder NDPI
Description: Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
Study: NCT03025698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Tablet for oral use, once daily or Powder for oral suspension (PfOS), once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hATG
Description: Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hATG
Description: Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA
Description: Cyclosporine (CsA) will be by supplied as either oral capsules or oral solution, administered twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA
Description: Cyclosporine (CsA) will be by supplied as either oral capsules or oral solution, administered twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA
Description: Cyclosporine (CsA) will be by supplied as either oral capsules or oral solution, administered twice a day
Study: NCT02344602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Oral tablet, 80mg, OD, 8 weeks
Study: NCT04367948

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG and 68Ga-NOTA-FAPI04 PET/CT
Description: Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG and 18F-NOTA-FAPI04 PET/CT
Description: Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
Study: NCT03751761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab, tremelimumab, paclitaxel
Description: Durvalumab, 1500 mg Q4W for 12 months Tremelimumab 75 mg Q4W for up to 4 doses/cycles Paclitaxel iv D1, D8, D15 Q4W (from 60mg/m2 to 80mg/m2)
Study: NCT04807452

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength and balance training
Description: Passive ROM to possible level of knee (flexion and extension), ankle (dorsiflexion and plantar flexion), forefoot (inversion and eversion) and toe (flexion and extension, adduction and abduction) joints.Resisted flexion and extension of knee, dorsiflexion and planter flexion of ankle, inversion and eversion of foot, flexion/extension, and abduction/adduction of toe with help of thera-band.The exercise prescription for strength training was made at approximately 50% of the estimated 1-RM. Exercise progression was achieved by instructing participants to increase the weight lifted in a specific exercise when they could perform 2 sets of 10-12 repetitions without maximal exertion on 2 consecutive training days. On basis of Borg Rating of Perceived Exertion of 10 to 13.Tandem leg stance for first 2 weeks and then it was progressed to Single leg stance toe and heel stance.For dynamic balance:backward walk Tandem walk and sideways walk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobics training
Description: After the baseline assessment, the participant in the Group B received Aerobic exercise with routine medical care.~All patients were followed for 3 days a week for 8 weeks treatment. Control Group received aerobic training. Control group received stretching exercise for 10 minutes and then treadmill walk for 10 minutes and then stationary bicycle for 10 minutes, and steppers for 10 minutes and 5 minute cool down .
Study: NCT03932253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FCN-159
Description: Administered orally once a day
Study: NCT02797899

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Fibrin
Description: Native growth factors

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Fibrin
Description: Native growth factors
Study: NCT04324606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19
Description: A single dose of 5x10\^10vp of ChAdOx1 nCoV-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19
Description: A single dose of 5x10\^10vp of ChAdOx1 nCoV-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19
Description: A single dose of 5x10\^10vp of ChAdOx1 nCoV-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19
Description: A single dose of 5x10\^10vp of ChAdOx1 nCoV-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19
Description: A single dose of 5x10\^10vp of ChAdOx1 nCoV-19
Study: NCT05872789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam 1% oral gel
Description: Diazepam 1% used with topic oral gel on tongue and palate twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral gel used on tongue and palate twice daily.
Study: NCT00777387

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: slow-freeze
Description: Slow-freeze-rapid-thaw procedure of oocytes is characterized by prolonged exposure of the cell to cryoprotectants in a low metabolic state at very low temperatures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vitrification
Description: Vitrification is the process by which water is prevented from forming ice due to the viscosity of a highly concentrated cryoprotectant cooled at an extremely rapid rate
Study: NCT00459563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 200,000 IU once weekly for 3 weeks (600,000 IU total dose)
Study: NCT01181895

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhalation Powder Diskus
Description: Placebo inhalation powder inhaled orally twice daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Inhalation Powder Diskus
Description: Placebo inhalation powder inhaled orally twice daily for 12 weeks
Study: NCT02780349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WIRION
Description: Embolic Protection System
Study: NCT02877485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 2 sprays sprayed to both nostrils daily for 42 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 2 sprays sprayed to both nostrils daily for 42 days.
Study: NCT00459563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcitriol
Description: calcitriol 0.5 mcg twice a day for 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a week for 3 weeks
Study: NCT02569879

Intervention type: OTHER
Intervention: Pertussis maternal immunization
Description: Retrospective time trend analysis before and after pertussis maternal immunization in Bogota, Colombia.

Intervention type: OTHER
Intervention: Pertussis maternal immunization
Description: Retrospective time trend analysis before and after pertussis maternal immunization in Bogota, Colombia.
Study: NCT04207658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Valsalva's Style Pushing
Description: The second stage of labour is defined as the time passed after the cervical dilatation reaches 10cm. The expulsion stage is the time between the sight of baby's head in the vulva and the end of labour. the participants are given information about the study after self introduction of each gravid is done for completing baseline obstetric data forms by midwives. Also, blood samples for pre and postpartum haemoglobin level changes are collected. The perineal area is examined for postpartum tears through pad checks. Vital findings (respiration, pulse and TA) are evaluated prior to their transfer to the delivery room. Just after the birth, mothers are tested for pH, pO2, pCO2 and lactate levels in blood while the newborns are tested for pH, pO2 (mmHg) and pCO2 levels through umbilical artery along with 1st min and 5 min APGAR analysis. The visual scale is utilized for determination of first 24-hour fatigue and they are recorded in follow-up forms.
Study: NCT01291186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPV6NO
Description: intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPV7NO
Description: intrathecal bupivacaine 7 mg for BMI less than 27.5 kg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPV8NO
Description: intrathecal bupivacaine 8 mg for BMI less than 27.5 kg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPV9NO
Description: intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPV10NO
Description: intrathecal bupivacaine 10 mg for BMI less than 27.5 kg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPV11NO
Description: intrathecal bupivacaine 11 mg for BMI less than 27.5 kg/m2
Study: NCT02877485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ayr saline nasal mist
Description: 110mcg (2 sprays) sprayed to both nostrils daily for 42 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ayr saline nasal mist
Description: 110mcg (2 sprays) sprayed to both nostrils daily for 42 days.
Study: NCT03063450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
Study: NCT01639079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Smoking Cessation Web Site
Description: Internet Stop Smoking site (TC5) with several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are: English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx
Study: NCT01623219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Exposure therapy refers to several cognitive behavioral treatment programs that involve confronting feared but safe thoughts, images, objects, situations, or activities in order to reduce unrealistic fear and anxiety. Exposure therapy for PTSD involves prolonged, imaginal exposure to the patient's traumatic memory and in vivo (in real life) exposure to trauma reminders. Prolonged exposure (PE) is a specific exposure therapy program that consists of five components: (1) psychoeducation (2) training in controlled breathing, (3) prolonged imaginal exposure to the trauma memory conducted in therapy sessions and repeated as homework, (4) prolonged in vivo exposure implemented as homework, and (5) processing of the traumatic material to correct maladaptive cognitions.
Study: NCT01291186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPV6O
Description: intrathecal bupivacaine 6 mg for BMI over 27.5 kg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPV7O
Description: intrathecal bupivacaine 7 mg for BMI over 27.5 kg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPV8O
Description: intrathecal bupivacaine 8 mg for BMI over 27.5 kg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPV9O
Description: intrathecal bupivacaine 9 mg for BMI over 27.5 kg/m2
Study: NCT02369133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol, patients in group S (n = 30) received 100 ml iv %0.9 NaCl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02261116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03798808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of fruits, vegetables and dairy products
Description: Family Nutriathlon was an eight-week, family-based nutrition program where children and their parents were encouraged to reach individual and team goals with respect to the quantity and variety of fruit, vegetable and dairy product consumption.
Study: NCT04303260

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercises
Description: The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical exercises
Description: The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation.
Study: NCT00216294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1068 (Synthetic Human Secretin)